Company intelligence / Profile preview

Evite

Wellington, New Zealand

Ownership: Private
Development stage: Other

Overview

Evithé Biotechnology is a botanical drug development company focused on creating evidence-based, multi-target medicines for inflammatory diseases and gastrointestinal health. Founded in 2021, the company utilizes a reverse pharmacology approach to identify and optimize plant-derived compounds, aiming to bridge the gap between traditional herbal medicine and modern pharmaceutical standards. Its pipeline includes botanical drug candidates for chronic and acute inflammation, as well as medical foods and herbal extracts for GI health. The company is currently advancing its lead programs toward Phase 1 and Phase 2 clinical trials.

Therapeutic areas: Infectious DiseasesImmunologyGastroenterology
Modalities: Botanical drugsHerbal extractsMedical foodsSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Evite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evite.

Explore the full profile